{
    "medicine_id": "c7a17af18a2d221af2f3d19511e80618952001af",
    "platform_id": "DB00847",
    "metadata": {
        "name": "Cystadrops 3 5 mg 1mL Solution",
        "composition": "3 5 mg 1mL Cysteamine",
        "clinical_particulars": {
            "therapeutic_indications": "The bitartrate salt of cysteamine is used for the oral treatment of nephropathic cystinosis and cystinuria in children 6 years old and above and adults L15616 The hydrochloride salt used in eye drop preparations is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis L15601 L15606",
            "contraindications": {
                "disease": "Two cases of human overdoses with cysteamine are recorded in the literature according to prescribing information In one case vomiting was immediate after the administration of cysteamine and the patient did not experience other symptoms A 200 to 250 mg kg dose was accidentally ingested by a healthy 13 month old child Vomiting and dehydration followed A full recovery was made after hospitalization and the replenishment of fluids L15646 There is no known antidote for an overdose with cysteamine In the case of an overdose provide supportive treatment especially to the cardiovascular and respiratory systems Hemodialysis may be useful in some cases due to the fact that cysteamine has poor plasma protein binding L15646",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Cystine accumulation is the cause of organ damage in cystinosis Cysteamine prevents the accumulation of cystine crystals in the body and is specifically prescribed to prevent kidney and eye damage A218931 L15601 L15616 Cysteamine converts cystine into a form that may easily exit cells preventing harmful accumulation L15606",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB01377",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium oxide"
                    },
                    {
                        "drugbank-id": "DB01390",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Sodium bicarbonate"
                    },
                    {
                        "drugbank-id": "DB06723",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Aluminum hydroxide"
                    },
                    {
                        "drugbank-id": "DB06724",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Calcium carbonate"
                    },
                    {
                        "drugbank-id": "DB08938",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magaldrate"
                    },
                    {
                        "drugbank-id": "DB09104",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium hydroxide"
                    },
                    {
                        "drugbank-id": "DB09281",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium trisilicate"
                    },
                    {
                        "drugbank-id": "DB09481",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium carbonate"
                    },
                    {
                        "drugbank-id": "DB13209",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Bismuth subnitrate"
                    },
                    {
                        "drugbank-id": "DB13249",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium silicate"
                    },
                    {
                        "drugbank-id": "DB13280",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Aluminium acetoacetate"
                    },
                    {
                        "drugbank-id": "DB13322",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Hydrotalcite"
                    },
                    {
                        "drugbank-id": "DB13486",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Magnesium peroxide"
                    },
                    {
                        "drugbank-id": "DB13595",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Almasilate"
                    },
                    {
                        "drugbank-id": "DB13626",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Aluminium glycinate"
                    },
                    {
                        "drugbank-id": "DB13650",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Aloglutamol"
                    },
                    {
                        "drugbank-id": "DB13829",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Calcium silicate"
                    },
                    {
                        "drugbank-id": "DB14517",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Aluminium phosphate"
                    },
                    {
                        "drugbank-id": "DB00213",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Pantoprazole"
                    },
                    {
                        "drugbank-id": "DB00338",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Omeprazole"
                    },
                    {
                        "drugbank-id": "DB00448",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Lansoprazole"
                    },
                    {
                        "drugbank-id": "DB00736",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Esomeprazole"
                    },
                    {
                        "drugbank-id": "DB01129",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Rabeprazole"
                    },
                    {
                        "drugbank-id": "DB05351",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Dexlansoprazole"
                    },
                    {
                        "drugbank-id": "DB13762",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Dexrabeprazole"
                    },
                    {
                        "drugbank-id": "DB15246",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Salvianolic acid A"
                    },
                    {
                        "drugbank-id": "DB14048",
                        "description": "The bioavailability of Cysteamine can be decreased when combined with Sodium zirconium cyclosilicate"
                    },
                    {
                        "drugbank-id": "DB00334",
                        "description": "Olanzapine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00501",
                        "description": "Cimetidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00585",
                        "description": "Nizatidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00863",
                        "description": "Ranitidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00927",
                        "description": "Famotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00940",
                        "description": "Methantheline can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB01069",
                        "description": "Promethazine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB01142",
                        "description": "Doxepin can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB06216",
                        "description": "Asenapine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB08805",
                        "description": "Metiamide can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB08806",
                        "description": "Roxatidine acetate can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB12770",
                        "description": "Lafutidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB12884",
                        "description": "Lavoltidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB13760",
                        "description": "Niperotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00751",
                        "description": "Epinastine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects"
                    },
                    {
                        "drugbank-id": "DB00898",
                        "description": "The risk or severity of adverse effects can be increased when Ethanol is combined with Cysteamine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}